SLC13A5 and fatty liver disease: Recent studies have shown that expression levels of this transporter in human liver might be associated with non-alcoholic fatty liver [26]; analysis of mechanistic aspects of this phenomenon has revealed involvement of the pro-inflammatory cytokine interleukin-6 in the upregulation of SLC13A5 in hepatocytes in association with fatty liver.